Bicycle Therapeutics (BCYC) Return on Capital Employed (2019 - 2026)
Bicycle Therapeutics (BCYC) reported Return on Capital Employed of 38.1% for Q1 2026, down 931.0% on a YoY basis from 4.58% in Q1 2025, and down 5.44% quarter-over-quarter from 36.13% in Q4 2025.
Bicycle Therapeutics (BCYC) Return on Capital Employed (2019 - 2026) Analysis & Trends
Bicycle Therapeutics has reported Return on Capital Employed for 8 years, with the latest figure at 38.1% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 931.0% year-over-year to 38.1%; the trailing twelve-month figure through Mar 2026 stood at 38.1% (down 931.0% YoY), and the FY2025 full-year result was 31.66%, down 206.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 38.1%, down from 36.13% in the prior quarter.
- The five-year high for Return on Capital Employed was 17.73% in Q1 2022, with the low at 39.79% in Q3 2025.
- Historically, Return on Capital Employed has averaged 30.91% across 5 years, with a median of 34.47% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 1509 bps — and 2025, when it slumped 1956 bps.
- Bicycle Therapeutics' Return on Capital Employed stood at 32.36% in 2022, then fell by 7 bps to 34.69% in 2023, then surged by 33 bps to 23.07% in 2024, then slumped by 57 bps to 36.13% in 2025, then decreased by 5 bps to 38.1% in 2026.
- The last three Return on Capital Employed figures came in at 38.1% (Q1 2026), 36.13% (Q4 2025), and 39.79% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Bicycle Therapeutics | 278.04 Mn | 278.04 Mn | - | -38.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.10% |
| Dec 31, 2025 | -36.13% |
| Sep 30, 2025 | -39.79% |
| Jun 30, 2025 | -36.93% |
| Mar 31, 2025 | -28.79% |
| Dec 31, 2024 | -23.07% |
| Sep 30, 2024 | -20.24% |
| Jun 30, 2024 | -25.03% |
| Mar 31, 2024 | -34.47% |
| Dec 31, 2023 | -34.69% |
| Sep 30, 2023 | -35.23% |
| Jun 30, 2023 | -39.78% |
| Mar 31, 2023 | -35.74% |
| Dec 31, 2022 | -32.36% |
| Sep 30, 2022 | -26.29% |
| Jun 30, 2022 | -21.16% |
| Mar 31, 2022 | -17.73% |
| Dec 31, 2021 | -19.06% |
| Sep 30, 2021 | -28.93% |
| Jun 30, 2021 | -30.26% |